Abstract
COVID-19 has been a major public health concern for the past five years. While remarkable work has been done to develop therapies, there is still a need for more treatments to fight this disease. Recently, it was suggested that nisin, an FDA-approved antimicrobial compound, may interfere with SARS-CoV-2 entry into host cells. Here, we show that nisin does not inhibit SARS-CoV-2 replication in vitro. Surprisingly, nisin treatment leads to reduced host-cell death during infection in a dose-dependent manner, suggesting that nisin may mitigate SARS-CoV-2-induced pathology.